Africa has begun administering Lenacapavir, a revolutionary twice-yearly HIV-prevention injection that experts say could transform the continent’s battle against HIV.
Health authorities in South Africa, Eswatini and Zambia commenced rollout today after approving the injection for widespread use.
Lenacapavir, taken only twice a year, has demonstrated more than 99.9% effectiveness in preventing HIV transmission, offering a level of protection many health experts describe as “vaccine-like.” T
he medication provides a long-acting alternative to daily oral PrEP, addressing long-standing challenges with adherence and accessibility across high-risk communities.
The introduction of the injection marks a significant stride in public health efforts aimed at reducing new infections in regions with some of the highest HIV prevalence rates in the world.
Health officials have hailed the development as a “game-changer,” noting that its long-acting nature will greatly benefit young women, key populations, and communities with limited access to daily medication.
The rollout is part of a broader international initiative involving global health partners working to expand affordable access to advanced HIV-prevention tools.
With today’s deployment, African nations take a major step toward curbing HIV transmission and strengthening long-term strategies for an AIDS-free generation.
